With sales of its hepatitis C drugs falling and an oncology pipeline that has largely disappointed, bictegravir is vitally important for Gilead to defend and grow its dominant HIV franchise. Bictegravir, the company’s next-generation integrase inhibitor, suppressed the HIV virus in newly diagnosed patients better than dolutegravir, a similar, rival drug from GlaxoSmithKline , according to results from a mid-stage clinical trial announced Monday night.
Category: Oncology
China Biotech Taps Big Data as Next Weapon in War on Cancer
When Nisa Leung was pregnant with her first child in 2012, her doctor in Hong Kong offered her a choice. She could take a prenatal test that would require inserting a needle into her uterus, or pay $130 more for an exam that would draw a little blood from her arm.
China Biotech Taps Big Data as Next Weapon in War on Cancer
When Nisa Leung was pregnant with her first child in 2012, her doctor in Hong Kong offered her a choice. She could take a prenatal test that would require inserting a needle into her uterus, or pay $130 more for an exam that would draw a little blood from her arm.
Merck scores a hit with Keytruda, watches spending in 4Q
Merck & Co.’ s new cancer medicine Keytruda, a blockbuster nearly overnight, along with aggressive and ongoing cost cuts, helped to boost fourth-quarter profits by 21 percent.
Old Cancer Drug Gets 1,000%-Plus Price Hike in Frugal U.K.
The chemotherapy known as busulfan is more than six decades old, and part of doctors’ standard arsenal against leukemia. It’s not scarce, and by all accounts, it should be dirt cheap.
Johnson & Johnson’s Most Exciting Opportunity
Can cancer drug sales continue to soar? Here’s why cancer drugs could be Johnson & Johnson’s most exciting opportunity in 2017. Global spending on cancer drugs eclipsed $100 billion two years ago, and aging and longer-living populations worldwide have IMS Health projecting that global spending on cancer medicine could hit $150 billion in 2020.
3 Reasons Gilead Sciences Inc. Stock Could Rise
Here are three things that could get shares turned around. OK, so perhaps anything is a bit extreme.
3 Biotechs Likely to Be Acquired in 2017
The year is still young, but we’ve already seen acquisitions of Ariad and CoLucid . Which biotechs could be scooped up next in 2017? Here’s why Clovis Oncology The number of big companies battling to acquire Medivationin 2016 shows that the oncology space is hot.
Takeda Expands Cancer Business With $4.66 Billion Ariad Deal
Takeda Pharmaceutical Co. will expand its footprint in the U.S. oncology market with the $4.66 billion purchase of Ariad Pharmaceuticals Inc., adding one potential blockbuster in lung cancer and another already on-the-market therapy.
Merrimack Soars on $1 Billion Sale of Cancer Drugs to Ipsen
The Nasdaq-listed cancer drugs developer is up 43% in pre-market trading after promising shareholders special dividends worth more than its closing share price on Friday. Nasdaq-listed Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen for as much as $1.05 billion, including benchmark payments.
3 Takeover Candidates in the Drug Space
This commentary originally appeared on Real Money Pro at 7 a.m. ET Friday, Jan. 6. Click here to learn about this dynamic market information service for active traders. We expect quite a number of M&A deals in the health-care sector in 2017.
Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales
Years before becoming a top cancer specialist, Eric Winer used to save money on his own medical care by talking U.S. pharmacists into giving him expired treatments for free. Winer, who has a bleeding disorder known as hemophilia, knew the drugs would still work for a brief time after the official use-by date.